Skip to main content

Table 1 Clinical characteristics of 262 patients with IPF treated with antifibrotic therapy

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

  Switch-IPF cohort (n = 37) Non-Switch-IPF cohort (n = 225) Non-Switch-IPF Continued cases (n = 177) Non-Switch-IPF Discontinued cases (n = 48) Non-Switch IPF versus Switch-IPF
p value
Age, years 70.0 [65.5–74.0] 73.0 [68.0–77.0] 72.0 [67.5–76.0] 74.0 [68.0–79.0] 0.0616
Sex, male/female 31 (83.8%)/6 (16.2%) 185 (82.2%)/40 (17.8%) 147 (83.0%)/30 (17.0%) 38 (79.2%)/10 (20.8%) 1.000
cIPF/UIP/IPF 31 (83.8%)/6 (16.2%) 175 (77.8%)/50 (22.2%) 134 (75.7%)/43 (24.3%) 41 (85.4%)/7 (14.6%) 0.5186
Diagnosis to antifibrotic therapy, months 13.6 [1.7–31.5] 15.4 [2.8–47.2] 12.1 [2.6–44.1] 31.5 [5.6–66.1] 0.2324
Pirfenidone/Nintedanib 29 (78.4%), 8 (21.6%) 130 (57.8%), 95 (42.2%) 102 (57.6%)/75 (42.4%) 28 (58.3%)/ 20 (41.7%) 0.0184
History of AE 0 (0%) 33 (14.7%) 25 (14.1%) 8 (16.7%) 0.0067
Never/former & current smoker 6 (16.2%), 31 (83.8%) 46 (20.4%), 179 (79.6%) 37 (20.9%)/140 (79.1%) 9 (18.8%)/39 (81.3%) 0.6602
Smoking pack-year 40.0 [18.0–59.0] 30.0 [3.0–46.0] 30.8 [3.0–45.0] 30.0 [7.5–48.0] 0.1297
BMI, kg/m2 24.3 [21.3–25.3] 22.9 [20.7–25.4] 23.3 [21.4–25.7] 21.9 [19.5–23.5] 0.2329
Pulmonary function test
FVC, %-pred 73.2 [62.4–83.7] 67.7 [56.5–79.8] 68.3 [58.5–80.2] 61.4 [47.7–77.4] 0.1018
FEV1, %-pred 75.3 [67.6–87.6] 74.4 [63.3–92.2] 76.4 [64.5–90.9] 73.1[55.8–90.9] 0.7480
FEV1/FVC, % 83.4 [79.9–88.9] 86.4 [79.9–92.2] 85.4 [79.8–91.4] 90.2 [80.4–94.5] 0.0438
DLCO, % 62.2 [50.2–67.6] (n = 37) 58.3 [43.4–72.0] (n = 185) Unable to perform (n = 14) 58.4 [44.0–71.5] (n = 153) Unable to perform (n = 7) 57.6 [38.1–77.7] (n = 32) Unable to perform (n = 7) 0.3516
GAP stage, I, II, III 18 (48.6%), 19 (51.4%), 0 (0%) 76 (38.2%), 90 (45.2%), 33 (16.6%) 63 (39.4%), 74 (46.3%), 23 (14.4%) 13 (33.3%), 16 (41.0%), 10 (25.6%) 0.0267
6-min walk test
Distances, m 432 [345–515] (n = 28) 400 [310–484] (n = 134) 400 [308–484] (n = 116) 400 [180–482] (n = 18) 0.1990
Minimum SpO2 < 90% 19/28 (67.9%) 100/134 (74.6%) 87/116 (75.0%) 13/18 (72.2%) 0.4845
UCG
TRV ≥ 2.9 m/s 2 (8.7%) (n = 29) 24 (17.9%) (n = 134) 16 (15.4%) (n = 104) 8 (26.7%) (n = 30) 0.1719
Laboratory      
Hb, g/dl 14.0 [13.2–15.1] 13.5 [12.3–14.7] 13.6 [12.4–14.8] 13.3 [12.1–14.7] 0.0612
TP, g/dl 7.5 [7.2–7.9] 7.4 [6.9–7.8] 7.5 [7.0–7.8] 7.3 [6.7–7.8] 0.0855
Alb, g/dl 4.1 [4.0–4.2] 3.9 [3.6–4.1] 3.9 [3.6–4.1] 3.7 [3.5–4.0] 0.0006
LDH, U/L 241 [210–270] 230 [203–273] 228 [203–268] 244 [206–280] 0.8415
CRP, mg/dl 0.2 [0.1–0.5] 0.3 [0.1–0.6] 0.3 [0.1–0.6] 0.3 [0.1–0.6] 0.5156
KL-6, U/ml 1124 [776–1473] 1062 [798–1524] 1057 [796–1560] 1105 [817–1402] 0.7003
SP-D, ng/ml 232 [136–345] 249 [165–370] 247 [158–375] 251 [188–369] 0.7278
Treatment
None 30 (81.1%) 128 (56.9%) 126 (71.2%) 22 (45.8%) 0.0060
LTOT 6 (16.2%) 85 (37.8%) 65 (36.7%) 20 (41.7%) 0.0144
Flow rate during rest
< 1, 1–3, > 3, L/min 4, 2, 0 40, 42, 3 30, 32, 3 10, 10, 0  
Immunosuppressants 3 (8.1%) 50 (22.2%) 37 (20.9%) 13 (27.1%) 0.0486
 PSL 3 30 23 8  
 PSL + CyA 0 11 7 4  
 PSL + CPA   5 3 2  
 PSL + Tac   4 4 0  
  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, GAP Gender–Age–Physiology, UCG ultrasound echocardiogram, TRV Tricuspid regurgitant jet velocity, KL-6 Krebs von den Lunge-6, SP-D surfactant protein-D, LTOT long-term oxygen therapy, PSL prednisolone, CyA cyclosporine A, CPA cyclophosphamide, Tac tacrolimus